IL315996A - Cancer treatments using PRMT5 inhibitors in collaboration with MTA - Google Patents

Cancer treatments using PRMT5 inhibitors in collaboration with MTA

Info

Publication number
IL315996A
IL315996A IL315996A IL31599624A IL315996A IL 315996 A IL315996 A IL 315996A IL 315996 A IL315996 A IL 315996A IL 31599624 A IL31599624 A IL 31599624A IL 315996 A IL315996 A IL 315996A
Authority
IL
Israel
Prior art keywords
mta
cooperative
cancer treatments
prmt5 inhibitors
prmt5
Prior art date
Application number
IL315996A
Other languages
English (en)
Hebrew (he)
Inventor
Brian Belmontes
Edward Lau Yue Chan
Paul Hughes
Katherine Slemmons
Jan Sun
Original Assignee
Amgen Inc
Brian Belmontes
Edward Lau Yue Chan
Paul Hughes
Katherine Slemmons
Jan Sun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Brian Belmontes, Edward Lau Yue Chan, Paul Hughes, Katherine Slemmons, Jan Sun filed Critical Amgen Inc
Publication of IL315996A publication Critical patent/IL315996A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL315996A 2022-04-08 2023-04-07 Cancer treatments using PRMT5 inhibitors in collaboration with MTA IL315996A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263329010P 2022-04-08 2022-04-08
US202263345736P 2022-05-25 2022-05-25
PCT/US2023/017805 WO2023196545A1 (en) 2022-04-08 2023-04-07 Cancer treatments using mta-cooperative prmt5 inhibitors

Publications (1)

Publication Number Publication Date
IL315996A true IL315996A (en) 2024-11-01

Family

ID=86328467

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315996A IL315996A (en) 2022-04-08 2023-04-07 Cancer treatments using PRMT5 inhibitors in collaboration with MTA

Country Status (14)

Country Link
US (1) US20250228861A1 (https=)
EP (1) EP4504199A1 (https=)
JP (1) JP2025511399A (https=)
KR (1) KR20240169712A (https=)
CN (1) CN119317435A (https=)
AU (1) AU2023249277A1 (https=)
CA (1) CA3255376A1 (https=)
CL (1) CL2024003040A1 (https=)
IL (1) IL315996A (https=)
JO (1) JOP20240223A1 (https=)
MX (1) MX2024012431A (https=)
TW (1) TW202345844A (https=)
WO (1) WO2023196545A1 (https=)
ZA (1) ZA202407596B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202440126A (zh) * 2022-11-30 2024-10-16 美商安進公司 利用ｍｔａ協作的ｐｒｍｔ５抑制劑和ｍａｔ２ａ抑制劑之癌症治療
EP4637774A1 (en) * 2022-12-21 2025-10-29 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
AU2024356380A1 (en) * 2023-10-06 2026-04-02 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
TW202519223A (zh) * 2023-10-31 2025-05-16 大陸商康百達（四川）生物醫藥科技有限公司 一種吡啶衍生物及其在醫藥上的應用
WO2025098450A1 (zh) * 2023-11-08 2025-05-15 北京泰德制药股份有限公司 Prmt5抑制剂及其制备方法
WO2025113703A1 (zh) * 2023-12-01 2025-06-05 上海翰森生物医药科技有限公司 四并环类衍生物抑制剂、其制备方法和应用
WO2025157284A1 (zh) * 2024-01-26 2025-07-31 上海湃隆生物科技有限公司 包含prmt5抑制剂和化疗剂的药物组合物
WO2025157287A1 (zh) * 2024-01-26 2025-07-31 上海湃隆生物科技有限公司 包含prmt5抑制剂和egfr抑制剂的药物组合物
WO2025176054A1 (zh) * 2024-02-20 2025-08-28 华润医药研究院（深圳）有限公司 三环杂环类化合物及其制备方法和医药用途
WO2025194059A1 (en) * 2024-03-15 2025-09-18 Prelude Therapeutics Incorporated Combination treatment regimens - smarca2 degrader with taxane anticancer agent
WO2025207705A1 (en) * 2024-03-26 2025-10-02 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
WO2025213154A1 (en) * 2024-04-05 2025-10-09 Amgen Inc. Gastrointestinal cancer treatments using mta-cooperative prmt5 inhibitors
WO2025250569A1 (en) * 2024-05-29 2025-12-04 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors and mat2a inhibitors
WO2025265110A1 (en) * 2024-06-21 2025-12-26 Amgen Inc. Oral pharmaceutical compositions comprising a naphthyridine compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3129832A1 (en) * 2019-02-13 2020-08-20 Les Laboratoires Servier Combination therapies for use in treating cancer
JP7787819B2 (ja) * 2020-02-12 2025-12-17 アムジェン インコーポレイテッド 新規ｐｒｍｔ５阻害剤
AU2021400942A1 (en) * 2020-12-16 2023-07-06 Amgen Inc. PRMT5 inhibitors

Also Published As

Publication number Publication date
EP4504199A1 (en) 2025-02-12
AU2023249277A1 (en) 2024-10-17
TW202345844A (zh) 2023-12-01
CL2024003040A1 (es) 2025-02-21
WO2023196545A1 (en) 2023-10-12
ZA202407596B (en) 2025-06-25
US20250228861A1 (en) 2025-07-17
KR20240169712A (ko) 2024-12-03
MX2024012431A (es) 2024-11-08
JOP20240223A1 (ar) 2024-10-06
CN119317435A (zh) 2025-01-14
CA3255376A1 (en) 2023-10-12
JP2025511399A (ja) 2025-04-15

Similar Documents

Publication Publication Date Title
IL315996A (en) Cancer treatments using PRMT5 inhibitors in collaboration with MTA
IL321326A (en) Cancer therapies using PRMT5 inhibitors collaborate with MTA
PT4181920T (pt) Inibidor de kat6 e combinações para o tratamento do cancro da mama
IL304275A (en) Cancer treatment methods
IL312680A (en) Cancer treatment methods
IL320332A (en) Cancer treatment methods
IL316829A (en) Menin-MLL inhibitors for cancer treatment
IL314049A (en) PARP7 inhibitors
IL288665A (en) Methods for treating cancer using prmt5 inhibitors
IL326481A (en) PRMT5 inhibitor acting in conjunction with spirocyclic MTA
IL312650A (en) CDK4 inhibitor for cancer treatment
IL300171A (en) Combined treatment against cancer
IL325326A (en) Cancer treatment method with indulin inhibitors of kif18a
EP4511376A4 (en) Egfr inhibitors in cancer treatment
IL288003A (en) Cancer treatment methods using chk1 inhibitors
IL318816A (en) MTA-COOPERATIVE PRMT5 inhibitors for use in cancer treatment
GB202301902D0 (en) Combination therapy for cancer
HK40130580A (zh) 使用mta协作的prmt5抑制剂的癌症治疗
CA3307095A1 (en) Cancer treatments using mta-cooperative prmt5 inhibitors
CA3275829A1 (en) Cancer treatments using mta-cooperative prmt5 inhibitors
HK40121902A (en) Cancer treatments using mta-cooperative prmt5 inhibitors
GB202218395D0 (en) Cancer therapy
IL316016A (en) Combined treatment for cancer
CA3283117A1 (en) Prmt5 inhibitor for use in cancer therapy
HK40072866A (en) Methods of treating cancer using prmt5 inhibitors